Human IL-17F Protein, His Tag (MALS verified)
分子別名(Synonym)
IL-17F,Interleukin-17F,Cytokine ML-1
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human IL-17F, His Tag (ILF-H5244) is expressed from human 293 cells (HEK293). It contains AA Arg 31 - Gln 163 (Accession # Q96PD4-1).
Predicted N-terminus: His
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 16.8 kDa. The protein migrates as 22-25 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
白細(xì)胞介素-17F(IL17F)也稱為白細(xì)胞介蛋白-24(IL24)、細(xì)胞因子ML-1,是一種分泌的二硫鍵連接的同二聚體,屬于IL-17家族。在人類和小鼠中,IL-17家族至少有六個成員:IL-17A、IL-17B、IL-17C、IL-17D、IL-17E(也稱為IL-25)和IL-17F(也稱為IL-24)。IL-17代表了一個結(jié)構(gòu)相關(guān)的細(xì)胞因子家族,它們共享一個高度保守的C末端區(qū)域,但在N末端區(qū)域和不同的生物學(xué)作用上彼此不同。IL-17F/IL-24在活化的CD4+T細(xì)胞和活化的單核細(xì)胞中表達(dá),但在靜息狀態(tài)下不表達(dá)。IL17F/白細(xì)胞介素-24刺激其他細(xì)胞因子如IL-6、IL-8和粒細(xì)胞集落刺激因子的產(chǎn)生,并可以調(diào)節(jié)軟骨基質(zhì)的周轉(zhuǎn)。IL17F/IL-24刺激PBMC和T細(xì)胞增殖并抑制血管生成。IL17F缺陷是家族性6型念珠菌?。?/span>CANDF6)的原因。
關(guān)鍵字: IL-17F;IL-17F蛋白;IL-17F重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。